C. Ola Landgren, MD (IMAGE)
Caption
“In order to take it to the next level, you need to drill deeper. You have to be more sophisticated in your approach to the disease (multiple myeloma) and how to better treat all the different subtypes of disease that our patients have,” said Dr. C. Ola Landgren, who leads the Sylvester Myeloma Research Institute. “We are exiting the one-size-fits-all era, and we are entering an era of precision medicine for myeloma.”
Credit
Photo by Sylvester
Usage Restrictions
None
License
Original content